The value of ultrasonography combined with carbohydrate antigen 125 and 19-9 detection in the diagnosis of borderline ovarian tumors and prediction of recurrence

Abstract

ObjectiveThis study aimed to investigate the clinical value of ultrasonography combined with tumor markers in the diagnosis and prediction of recurrence of borderline ovarian tumors (BOTs) and analyze the value of the combination of two different auxiliary examinations in the diagnosis and prediction of recurrence of BOTs.MethodsHere, 221 patients with BOTs confirmed by postoperative pathology were enrolled. Their clinical data, including the ultrasonography features, tumor markers, and clinicopathological data, were retrospectively analyzed.ResultsThe statistical data of the 221 cases with BOTs were as follows: 94 (42.5%) with left-sided lesions, 102 (46.2%) with right-sided lesions, and 25 (11.3%) with bilateral lesions. Moreover, 93 cases (42.1%) had a borderline serous tumor, 110 (49.8%) had a borderline mucinous tumor, 12 (5.4%) had a borderline serous mucinous tumor, 2 (0.9%) had a borderline endometrioid tumor, 1 (0.5%) had a borderline Brenner tumor, and 2 (0.9%) had a clear cell BOT. There were 104 cases (47.1%) with a tumor diameter of ≤10 cm and 117 cases (52.9%) with a tumor diameter of >10 cm as suggested by ultrasonography. There were 89 cases (40.3%) with septation, 44 (19.9%) with papilla, and 97 (43.9%) with blood flow as demonstrated by ultrasonography. Carbohydrate antigen 125 (CA 125) was elevated in 132 cases (59.7%), and CA 19-9 was elevated in 52 cases (23.5%).ConclusionIn general, BOTs are difficult to diagnose preoperatively and have a certain recurrence rate. Ultrasonography combined with CA 125 and CA 19-9 is significant for the preoperative diagnosis and selection of surgical modality for BOTs and could be used as a guideline to achieve good preoperative preparation and avoid secondary surgery.

Comparison of Tumor Markers and Risk of Malignancy Index (RMI) in Borderline OvarianTumors Names of

“…But in our study we could not nd any difference for Ca125 or 19 − 9 levels between serous and mucinous groups. But we found signi cantly larger cysts in mucinous borderline group than serous as in literature (22)(23). And also mucinous BOTs are commonly unilateral and have higher invasive occurance rate than serous type (16,23).…”

Comparison of the diagnostic efficiency between the O-RADS US risk stratification system and doctors’ subjective judgment

“…The imaging findings of ovarian tumors are complex and diverse. The benign, borderline and malignant ovarian tumors with overlapping imaging features always lack specific imaging features [24][25][26]. Even experienced gynecological ultrasound experts can only infer the possible source of ovarian tumors (such as epithelial or sex cord stromal sources) and the possibility of benign or malignant tumors by their subjective judgment.…”

Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment

“…The diagnosis of ovarian cancer has seen significant progress, driven by the integration of biomarkers and advanced imaging techniques (Li and Wang, 2023). For instance, a combination of mucin 16 (MUC16 also known as carbohydrate antigen 125 or CA-125), with pelvic ultrasound achieved a higher specificity for ovarian cancer detection (Niu et al, 2023), and the synergy of MUC16 and Schematic diagram representing the currently integrated diagnostic, imaging, and therapeutic approaches in ovarian cancer.…”